

Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations. Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations.
Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Owner
Owner
Owner
Owner
Owner
Owner
Contributor
Therapeutic Relevance
The proposed mechanism is scientifically plausible and well-grounded. HSC aging is a biologically validated driver of immune decline, anemia, and hematologic malignancies. The project leverages single-cell RNA-seq analysis of ~850,000 transcriptomes to identify differentially expressed genes between young and old HSCs, with highly statistically significant results (adjusted p-values with -log10 >200-300). The identified targets (NR4A1/2, UHRF1, CD38, CCR9, etc.) are biologically relevant and supported by existing literature. The multi-modal intervention strategy targeting transcriptional stress responses, epigenetic regulation, and protein homeostasis simultaneously is scientifically sound. However, the score is not a 5 because: (1) all work remains computational with zero experimental validation of the proposed targets, (2) the AubrAI-generated hypothesis, while interesting, is AI-generated and unvalidated, and (3) the leap from bioinformatics targets to functional rejuvenation remains unproven. The biological rationale is strong but the mechanistic link between modulating these specific genes and achieving meaningful HSC rejuvenation is still hypothetical.
Therapeutic Optionality
The concept demonstrates strong therapeutic optionality. HSC rejuvenation could address multiple therapeutic areas: (1) age-related immune decline and immunosenescence, (2) anemia and cytopenias, (3) prevention of myelodysplastic syndromes and leukemia, (4) improved vaccine responses in the elderly, and (5) broader regenerative medicine applications. The multi-modal approach (mRNA, siRNA, small molecules, CRISPR, gene therapy) provides flexibility in intervention modality. The platform nature of the scRNA-seq/AI discovery engine could potentially be applied to other stem cell types beyond HSCs. Multiple delivery strategies are contemplated (electroporation for in vitro, CD117-targeted lipid nanoparticles for in vivo). The identified targets like CD38 and RhoA have relevance beyond just HSC biology. Score is not a 5 because the concept is currently narrowly focused on HSCs and the broader applicability remains speculative at this early stage.
Intellectual Property
The IP position is moderate with both strengths and risks. Strengths: (1) the specific combination of targets identified for multi-modal HSC rejuvenation could be novel and patentable, (2) the proprietary scRNA-seq datasets and computational pipelines add differentiation, (3) no patents have been filed yet but the project lists patent filing as a planned outcome. Risks: (1) many of the individual targets (CD38, RhoA, NR4A family, rapamycin/mTOR) are well-known in the aging and hematopoiesis literature, creating significant prior art concerns, (2) several proposed small molecules (Fasudil, rapamycin, cromolyn sodium) are already FDA-approved or in development for other indications, limiting composition-of-matter claims, (3) the use of publicly available scRNA-seq datasets means competitors could independently identify similar targets, (4) no IP has been filed to date, leaving the project vulnerable to being scooped, and (5) the AubrAI tool's contribution raises questions about inventorship and IP ownership. The novelty likely lies in the specific combination and temporal coordination of interventions rather than individual targets, which is a narrower IP position.